Santen Pharmaceutical (OTCMKTS:SNPHY) Shares Gap Down - Here's Why

Key Points

• Santen Pharmaceutical shares gapped down prior to trading Thursday, opening at $11.9450 after a $12.58 close, a roughly 5.0% decline on light volume (362 shares).
• The company has a market cap of $3.84 billion and a very low price‑to‑earnings ratio of 0.10; Santen is a Japan‑based specialty pharmaceutical firm focused on ophthalmology treatments and related surgical/diagnostic products.

Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY - Get Free Report)'s share price gapped down prior to trading on Thursday . The stock had previously closed at $12.58, but opened at $11.9450. Santen Pharmaceutical shares last traded at $11.9450, with a volume of 362 shares.

Santen Pharmaceutical Stock Down 5.0%

The stock has a market cap of $3.84 billion and a price-to-earnings ratio of 0.10. The company's 50-day simple moving average is $11.00 and its 200-day simple moving average is $10.65.

Santen Pharmaceutical Company Profile

Santen Pharmaceutical Co, Ltd. is a Japan‐based specialty pharmaceutical company focused exclusively on ophthalmology. Headquartered in Osaka, Santen engages in the research, development, manufacture and marketing of prescription and over‐the‐counter products for the diagnosis and treatment of eye diseases. Its core product portfolio includes therapies for glaucoma, dry eye, retinal disorders, uveitis and post‐operative care, as well as surgical equipment and diagnostic agents designed to support comprehensive eye care.

With roots tracing back to the late 19th century, Santen has grown from a domestic manufacturer to a global ophthalmic specialist.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.